Modifying the structure of dinuclear ruthenium complexes with antitumor activity
暂无分享,去创建一个
[1] I. Bratsos,et al. Ruthenium Anticancer Compounds: Challenges and Expectations , 2007 .
[2] L. Juillerat-Jeanneret,et al. Remarkable Anticancer Activity of Triruthenium-Arene Clusters Compared to Tetraruthenium-Arene Clusters , 2007 .
[3] Andrew D. Phillips,et al. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. , 2007, Journal of medicinal chemistry.
[4] Anna F. A. Peacock,et al. Osmium(II) and ruthenium(II) arene maltolato complexes: rapid hydrolysis and nucleobase binding. , 2007, Chemistry.
[5] P. Dyson,et al. Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy , 2006 .
[6] R. Scopelliti,et al. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis. , 2006, Inorganic chemistry.
[7] B. Keppler,et al. Electrospray ionization mass spectrometric study on the coordination behavior of dacarbazine towards transition metal ions , 2006 .
[8] C. Orvig,et al. Metal complexes of maltol and close analogues in medicinal inorganic chemistry. , 2006, Chemical Society reviews.
[9] M. Jakupec,et al. From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). , 2006, Journal of inorganic biochemistry.
[10] Christian G Hartinger,et al. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. , 2006, Chemical reviews.
[11] P. Dyson,et al. Metal-based antitumour drugs in the post genomic era. , 2006, Dalton transactions.
[12] M. Jakupec,et al. Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. , 2006, Dalton transactions.
[13] I. Tavernelli,et al. Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds , 2006 .
[14] Katherine H Thompson,et al. Metal complexes in medicinal chemistry: new vistas and challenges in drug design. , 2006, Dalton transactions.
[15] Anna F. A. Peacock,et al. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions. , 2006, Journal of the American Chemical Society.
[16] P. Sadler,et al. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes. , 2005, Chemical communications.
[17] G. Stingeder,et al. Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins , 2005 .
[18] P. Dyson,et al. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. , 2005, Journal of medicinal chemistry.
[19] M. Galanski,et al. 1,1'‐Bis(oxazolin‐2‐yl)ferrocenes: An Investigation of Their Complexation Behavior toward [Pd(η3‐allyl)Cl]2 , 2005 .
[20] U. Jaehde,et al. Analysis of Platinum Adducts with DNA Nucleotides and Nucleosides by Capillary Electrophoresis Coupled to ESI‐MS: Indications of Guanosine 5′‐Monophosphate O6–N7 Chelation , 2004, Chembiochem : a European journal of chemical biology.
[21] M. Jakupec,et al. Gallium in cancer treatment. , 2004, Current topics in medicinal chemistry.
[22] A. Timerbaev,et al. Platinum metallodrug‐protein binding studies by capillary electrophoresis‐inductively coupled plasma‐mass spectrometry: Characterization of interactions between Pt(II) complexes and human serum albumin , 2004, Electrophoresis.
[23] B. Keppler,et al. A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins. , 2004, Journal of inorganic biochemistry.
[24] J. Schellens,et al. A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent , 2004, Clinical Cancer Research.
[25] Thomas J. Meyer,et al. Comprehensive Coordination Chemistry II , 2004 .
[26] G. Allmaier,et al. Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy , 2004 .
[27] M. Galanski,et al. Synthesis, crystal structures, and electrospray ionisation mass spectrometry investigations of ether- and thioether-substituted ferrocenes , 2003 .
[28] C. S. Allardyce,et al. Synthesis and characterisation of some water soluble ruthenium(II)–arene complexes and an investigation of their antibiotic and antiviral properties , 2003 .
[29] T. Uzbay,et al. New analgesic and antiinflammatory agents 4(1H)-pyridinone derivatives. , 2002, European journal of medicinal chemistry.
[30] L. Gano,et al. Synthesis, chelating properties towards gallium and biological evaluation of two N-substituted 3-hydroxy-4-pyridinones. , 2000, Journal of inorganic biochemistry.
[31] K. Severin,et al. Halfsandwich complexes of ruthenium(II), rhodium(III) and iridium(III) with N-substituted 3-hydroxy-2-methyl-4-pyridone ligands , 1999 .
[32] K. Polborn,et al. Metallorganische Verbindungen mit N-substituierten 3-Hydroxy-2-methyl-4-pyridon-Liganden: quadratisch-planare Rhodium(I)-, Iridium(I)- und Palladium(II)-Komplexe , 1999 .
[33] Ying Liang,et al. Assembly of Mesoporous Lamellar Silicas with Hierarchical Particle Architectures , 1997 .
[34] Rln Harris. Potential wool growth inhibitors. Improved syntheses of mimosine and related 4(1H)-Pyridones , 1976 .
[35] N. Farrell,et al. Metal Complexes as Drugs and Chemotherapeutic Agents , 2003 .
[36] C. S. Allardyce,et al. [Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo- [3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells , 2001 .
[37] B. Noll,et al. Chemistry and Pharmacokinetics of Gallium Maltolate, a Compound With High Oral Gallium Bioavailability , 2000, Metal-based drugs.